160 related articles for article (PubMed ID: 34814056)
1. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
[TBL] [Abstract][Full Text] [Related]
3. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
4. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
5. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.
da Silva SM; Amorim IF; Ribeiro RR; Azevedo EG; Demicheli C; Melo MN; Tafuri WL; Gontijo NF; Michalick MS; Frézard F
Antimicrob Agents Chemother; 2012 Jun; 56(6):2858-67. PubMed ID: 22411610
[TBL] [Abstract][Full Text] [Related]
7. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
[TBL] [Abstract][Full Text] [Related]
8. IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis.
de Oliveira Cardoso JM; de Brito RCF; Costa AFP; Siqueira Mathias FA; Soares Reis LE; Vieira JFP; de Oliveira Aguiar Soares RD; Reis AB; Roatt BM
Mol Immunol; 2021 Sep; 137():20-27. PubMed ID: 34182228
[TBL] [Abstract][Full Text] [Related]
9. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
Medkour H; Bitam I; Laidoudi Y; Lafri I; Lounas A; Hamidat HK; Mekroud A; Varloud M; Davoust B; Mediannikov O
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008947. PubMed ID: 33338041
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.
Miret J; Nascimento E; Sampaio W; França JC; Fujiwara RT; Vale A; Dias ES; Vieira E; da Costa RT; Mayrink W; Campos Neto A; Reed S
Vaccine; 2008 Mar; 26(12):1585-94. PubMed ID: 18328956
[TBL] [Abstract][Full Text] [Related]
11. A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania infantum.
Kasabalis D; Chatzis MK; Apostolidis K; Petanides T; Athanasiou LV; Xenoulis PG; Mataragka A; Ikonomopoulos J; Leontides LS; Saridomichelakis MN
Exp Parasitol; 2020 Jul; 214():107903. PubMed ID: 32360142
[TBL] [Abstract][Full Text] [Related]
12. Improved efficacy of meglumine antimoniate incorporated in anionic liposomes against Leishmania infantum infecting canine macrophages.
Ortega V; Radaic A; de Jesus MB; de Paula E; Giorgio S
J Pharm Pharmacol; 2022 Jun; 74(6):896-904. PubMed ID: 34289045
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
[TBL] [Abstract][Full Text] [Related]
15. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
[TBL] [Abstract][Full Text] [Related]
17. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.
Riera C; Valladares JE; Gállego M; Aisa MJ; Castillejo S; Fisa R; Ribas N; Carrió J; Alberola J; Arboix M
Vet Parasitol; 1999 Jul; 84(1-2):33-47. PubMed ID: 10435789
[TBL] [Abstract][Full Text] [Related]
18. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
19. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
[TBL] [Abstract][Full Text] [Related]
20. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.
Gradoni L; Maroli M; Gramiccia M; Mancianti F
Med Vet Entomol; 1987 Oct; 1(4):339-42. PubMed ID: 2979550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]